- Home
- FENC vs RLTY Comparison
FENC vs RLTY Comparison
Compare FENC & RLTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FENC | RLTY |
|---|---|---|
| Founded | 1996 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 264.2M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FENC | RLTY |
|---|---|---|
| Price | $8.91 | $15.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 385.5K | 44.3K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.35% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $65.12 | N/A |
| Revenue Next Year | $41.08 | N/A |
| P/E Ratio | $870.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $14.04 |
| 52 Week High | $10.45 | $15.97 |
Technical Indicators
Market Signals| Indicator | FENC | RLTY |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 54.41 |
| Support Level | $7.40 | $14.93 |
| Resistance Level | $9.15 | $15.88 |
| Average True Range (ATR) | 0.52 | 0.25 |
| MACD | -0.21 | -0.01 |
| Stochastic Oscillator | 20.41 | 57.89 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income. Its secondary investment objective is capital appreciation. The fund invests the majority of its managed assets in real estate-related investments and preferred and other income securities.